Vertex Pharmaceuticals Incorporated (VIE:VRTX)
Austria · Delayed Price · Currency is EUR | Market Cap | 92.66B -8.3% |
| Revenue (ttm) | 10.60B +10.1% |
| Net Income | 3.76B |
| EPS | 14.62 |
| Shares Out | n/a |
| PE Ratio | 24.63 |
| Forward PE | 21.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 365.10 |
| Previous Close | 366.70 |
| Day's Range | 364.50 - 365.10 |
| 52-Week Range | 313.80 - 430.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex announces U.S. FDA accepted BLA submission for povetacicept
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration, FDA, has accepted its Biologics License Application, BLA, submission for povetacicept, an investigational engineered fusi...
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission ...
Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Expanded from CF to pain, hematology, and renal franchises, with strong launches and pipeline progress. ALYFTREK is now the CF standard, JOURNAVX is rapidly growing in pain, and the renal franchise is poised for major impact with multiple late-stage programs.
Vertex Pharmaceuticals assumed with a Buy at Truist
Truist assumed coverage of Vertex Pharmaceuticals (VRTX) with a Buy rating and price target of $542, up from $525. The firm believes Vertex’s emerging kidney franchise can grow into blockbuster…
Vertex announces Health Canada acceptance of NDS for suzetrigine
Vertex Pharmaceuticals (VRTX) announced that Health Canada has accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Suzetrigine is a ...
Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Growth in CF is driven by innovation, younger patient access, and global expansion, with ALYFTREK and TRIKAFTA label expansions fueling future gains. JOURNAVX is set for significant revenue growth as coverage expands. Povi shows strong efficacy in IgAN and is advancing in multiple indications.
Vertex to Participate in Upcoming May Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial...
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $607 and keeps an Overweight rating on the shares.
Vertex Pharmaceuticals announces Casgevy reimbursement agreement
Vertex Pharmaceuticals (VRTX) Incorporated announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY. This agreement secures sust...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap...
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $616 from $612 and keeps an Overweight rating on the shares. Q1 results were “uneventful” and FY26 guidance…
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the shares. Shares have been weak…
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $436 from $437 and keeps a Hold rating on the shares. The firm said they reported a slight top-line…
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $572 from $577 and keeps an Outperform rating on the shares. The firm notes revenue was in line while…
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
The company states: “Today, Vertex (VRTX) announced that it has decided to discontinue the Phase 1/2 study of the investigational inhaled CFTR mRNA candidate for cystic fibrosis, VX-522. Despite exten...
Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 8% year-over-year to $2.99B, with strong growth in CF and new products like ALYFTREK, CASGEVY, and JOURNAVX. Robust R&D and commercial execution support 2026 guidance of $12.95–$13.1B revenue and over $500M from non-CF products.
Vertex Pharmaceuticals Earnings release: Q1 2026
Vertex Pharmaceuticals released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q1 2026
Vertex Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Vertex Pharmaceuticals Quarterly report: Q1 2026
Vertex Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 4, 2026.
Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
Reports Q1 revenue $2.99B, consensus $3.00B. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute…
Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
16:02 EDT Vertex Pharmaceuticals (VRTX) affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Reports First Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 ...
Vertex Pharmaceuticals Proxy statement: Proxy filing
Vertex Pharmaceuticals filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.